Johnson & Johnson has halved the size of its collaboration with Bavarian Nordic on vaccine development, jettisoning its stake in shots targeting human papillomavirus (HPV) and hepatitis B virus (HBV).

The EMA's human medicines committee has recommended approval for Bavarian Nordic's chikungunya vaccine, which is shaping up to be the first alternative to a rival shot from Valneva. The CHIKV VLP ...

Still, there was a silver lining for Bavarian Nordic, as the vaccine specialist’s travel health business—which includes shots for rabies and tick-borne encephalitis (TBE), among others—grew 22%.